Clinical Trial Update: Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction [Phase 3]

View source ↗

Summary

A Phase III trial evaluating a fixed-dose combination of etodolac and cyclobenzaprine versus individual components for pain control after impacted third molar e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dental Pain
• Pain Acute

Drugs mentioned

• Cyclobenzaprine (cyclobenzaprine)
• Etodolac (Etodolac)
• Etodolac 400 mg / Cyclobenzaprine 10 mg fixed-dose combination (etodolac + cyclobenzaprine)

Snippet

Sponsor: Apsen Farmaceutica S.A. | Conditions: Pain, Acute | Phase 3 | Status: TERMINATED